Leukemia, Lymphocytic, Chronic, B-Cell: all 1,648 studies
Page 2 of 17. Open to participants first (245), then studies with results posted, then the rest; newest registration first within each.
- A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell MalignanciesRecruitingNCT06708897Phase 1
- A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.RecruitingNCT06697184Phase 1/2
- Effects of a Strength Physical Exercise Program in Chronic Lymphocytic Leukemia PatientsNot yet recruitingNCT06654206Early Phase 1
- Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)RecruitingNCT06644183Phase 1/2
- A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaRecruitingNCT06588478Phase 2
- A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell MalignanciesRecruitingNCT06564038Phase 1/2
- The Real World Study of BTK Inhibitor in the Treatment of Chronic Lymphocytic Leukemia in ChinaNot yet recruitingNCT06557304
- AQUALIS:QoL of CLL Patients Treated With Acalabrutinib in France, Retrospective Study Based on Data From PLATON DatabaseRecruitingNCT06548152
- Zanubrutinib With Obinutuzumab in Untreated Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaRecruitingNCT06544785Phase 2
- A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.RecruitingNCT06542250Phase 1/2
- DZD8586 in Patients With Relapsed or Refractory CLL/SLL (TAI-SHAN8)RecruitingNCT06539182Phase 2
- Hematopoiesis in MBL and CLL Versus Healthy Age-Matched Control SubjectsRecruitingNCT06536452
- Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)RecruitingNCT06533579Phase 1/2
- A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell MalignanciesRecruitingNCT06528301Phase 1
- A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)RecruitingNCT06520098Phase 2
- Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene TherapiesRecruitingNCT06508775Not applicable
- Safety and Efficacy of KLS-1 Monotherapy in Malignant NeoplasmsRecruitingNCT06506643Phase 1/2
- The Real World Study of Zanubrutinib in the Treatment of Chronic Lymphocytic Leukemia in ChinaNot yet recruitingNCT06489184
- Description of the Immune Deficiency in Patients With Untreated Chronic Lymphocytic Leukemia and Search for Predictive Factors of Infectious RiskRecruitingNCT06475469Not applicable
- Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKiRecruitingNCT06466122Phase 2
- A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)RecruitingNCT06428019Phase 3
- Risk and Clinical Consequences of Low Count Monoclonal B-cell Lymphocytosis (LC MBL)Not yet recruitingNCT06416267
- Wisconsin Ginseng for Decreasing Cancer Related FatigueRecruitingNCT06395441Phase 3
- Investigating the Role of Energy Balance Modification on Health Responses in Chronic Lymphocytic LeukaemiaRecruitingNCT06379282Not applicable
- MRD Guided Sonrotoclax and Zanubrutinib in Newly Diagnosed CLL/SLLNot yet recruitingNCT06367374Phase 2
- Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for LeukemiasRecruitingNCT06364423Phase 1/2
- Biological and Clinical Efficacy of Shingrix in Patients With CLLNot yet recruitingNCT06364033Not applicable
- Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic LeukemiaRecruitingNCT06333262Phase 2
- Benefits of Individual Physical Activity Intervention on Health-related Quality of Life in Participants With Chronic Lymphocytic LeukemiaRecruitingNCT06299540
- Preliminary Assessment of [18F]BL40 in PET/CT ScansRecruitingNCT06224309
- Hypertension and Arrhythmias in CLL Patients Treated With BTK InhibitorsEnrolling by invitationNCT06211413
- B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic MalignanciesRecruitingNCT06191887Phase 1
- Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT StudyRecruitingNCT06151730
- A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)RecruitingNCT06136559Phase 3
- Outcomes of Unfit Patients With CLL Included in the GIMEMA LLC1114 Trial Who Discontinued Ibrutinib Due to Reasons Other Than Disease ProgressionNot yet recruitingNCT06084923
- CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell TransplantRecruitingNCT06059391Phase 2
- Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's TransformationRecruitingNCT06043674Phase 2
- Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic NeoplasmsRecruitingNCT06043011
- Safety Study of CC312 in Adult Patients With Relapsed/Refractory CD19 Positive B-cell Hematologic MalignanciesRecruitingNCT06037018Phase 1
- PICAROS - Acalabrutinib RWE on 1L CLL in SpainRecruitingNCT05999877
- Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLLRecruitingNCT05963217Phase 1
- A Clinical Trial on the Safety and Efficacy of TQB3909 Tablets in Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) .RecruitingNCT05959694Phase 1/2
- A Single Arm Study of Acalabrutinib Conbimed With Obinutuzumab in Chinese Patients With Previously Untreated CLLRecruitingNCT05950997Not applicable
- A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).RecruitingNCT05947851Phase 3
- Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic LymphomaRecruitingNCT05943496Phase 1
- A Study of Novel Anti-CD19 CAR-T in Patients With r/r B-Cell MalignanciesRecruitingNCT05932173Phase 1/2
- (CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin's Lymphoma (NHL)Not yet recruitingNCT05923502
- Phase IV Observational Study of Orelabrutinib in the Treatment of Chronic Lymphocytic Leukemia/Small Cell LymphomaRecruitingNCT05920668
- A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic MalignanciesRecruitingNCT05908409Phase 1/2
- Determining Clinical Study Experiences of Chronic Lymphocytic Leukemia PatientsNot yet recruitingNCT05899543
- "Don't Eat me" Signal in Hematological Malignancies: CD24 as New Target to Improve Anti-cancer Immunity.RecruitingNCT05888701
- The Effects of Exercise on Immune Phenotype of Indolent Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia PatientsRecruitingNCT05876923Not applicable
- Allo HSCT Using RIC and PTCy for Hematological DiseasesRecruitingNCT05805605Phase 2
- Incidence of Severe COVID-19 Infection in Patients With CLL or B-NHL Who Received Pre-exposure Prophylaxis With Tixagevimab and Cilgavimab in Italy.RecruitingNCT05803395
- A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell MalignanciesRecruitingNCT05780034Phase 1
- Safety and Efficacy of Allogenic CD19-CAR-NK Cells in Treatmenting r/r B-cell Hematologic MalignanciesRecruitingNCT05739227Early Phase 1
- Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or VenetoclaxRecruitingNCT05724121
- Familial B-cell Lymphoproliferative DisordersNot yet recruitingNCT05718986
- Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLLRecruitingNCT05702853Phase 1/2
- Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBLRecruitingNCT05694312Phase 2
- A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin LymphomaRecruitingNCT05645107Phase 3
- A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell MalignanciesRecruitingNCT05643742Phase 1/2
- Implanted Loop Recorders for Detection and Management of Arrhythmia With Bruton Tyrosine Kinase InhibitorsRecruitingNCT05643235Not applicable
- AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin LymphomaRecruitingNCT05602363Phase 1
- Study of SGR-1505 in Mature B-Cell NeoplasmsRecruitingNCT05544019Phase 1
- Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell MalignanciesRecruitingNCT05487651Phase 1
- Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid MalignanciesRecruitingNCT05418088Phase 1
- Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic LeukemiaRecruitingNCT05417165Phase 2
- Economic Analysis of Early vs Delayed Therapy in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma:RecruitingNCT05371808
- Polymorphism of ITGA4 Gene in Chronic Lymphocytic LeukemiaNot yet recruitingNCT05371392
- Ibrutinib Adapted to Response in Patients With CLLNot yet recruitingNCT05360758
- Evaluation of the Ambulatory Medical Assistance Nurse Program in Chronic Lymphocytic LeukemiaRecruitingNCT05350826Not applicable
- Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic LeukemiaRecruitingNCT05336812Phase 2
- Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer DetectionRecruitingNCT05334069
- Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular LymphomaRecruitingNCT05326308
- Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-DegraderRecruitingNCT05294731Phase 1/2
- Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic LeukemiaRecruitingNCT05281809Phase 2
- A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)RecruitingNCT05254743Phase 3
- Venetoclax Resistance Landscape in Chronic Lymphocytic LeukemiaRecruitingNCT05246345
- A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLLRecruitingNCT05197192Phase 3
- Pneumococcal Pneumonia Vaccine Series (PCV20 and PPSV23) in Patients With Chronic Lymphocytic Leukemia Associated Immunodeficiency, PROTECT CLL TrialRecruitingNCT05183854Phase 2
- Zanubrutinib and Venetoclax in CLL (ZANU-VEN)RecruitingNCT05168930Phase 2
- Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLLRecruitingNCT05147467Phase 2
- Selenious Yeast in CLL Patients w/o Indication of ChemotherapyRecruitingNCT05136378Not applicable
- A Study of NX-5948 in Adults With Relapsed/Refractory B-cell MalignanciesRecruitingNCT05131022Phase 1
- Profiling Program of Cancer Patients With Sequential Tumor and Liquid Biopsies (PLANET)RecruitingNCT05099068Not applicable
- A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic LeukemiaRecruitingNCT05091424Phase 1
- Two Step Haplo With Radiation ConditioningRecruitingNCT05031897Phase 2
- Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell LymphomaRecruitingNCT05020392Phase 3
- A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell MalignanciesRecruitingNCT05006716Phase 1/2
- Zebutinib Combined With Immunochemotherapy in the Treat of Newly Treated CLL Patients Without 17p-/TP53 MutationNot yet recruitingNCT04980859Phase 3
- Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 TrialRecruitingNCT04941716Phase 2
- Faecal Microbiota Transplantation After Allogeneic Stem Cell TransplantationRecruitingNCT04935684Phase 2
- Fixed-duration Therapy With Ibrutinib and Obinutuzumab (GA-101) in Treatment-naïve Patients With CLLRecruitingNCT04908228Phase 2
- Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)RecruitingNCT04895436Phase 2
- CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell MalignanciesRecruitingNCT04892277Phase 1
- Study on the Diagnosis and Management of CLL in Italy by GIMEMARecruitingNCT04867915
- Effects of Nicotinamide in Patients With Chronic Lymphocytic Leukemia With History of Non-melanoma Skin CancersRecruitingNCT04844528Phase 2
- A Study of NX-2127 in Adults With Relapsed/Refractory B-cell MalignanciesRecruitingNCT04830137Phase 1
- Lymph Node Microenvironment Modifications in Patients With CLL Treated With Venetoclax-based RegimensNot yet recruitingNCT04790045Phase 4